–News Direct–
PathAI, a global leader in AI-powered pathology, today announced the launch of AIM-TumorCellularity (AIM-TC), the latest algorithm product available for use by laboratories utilizing the AISight Image Management System (IMS).1
AIM-TC enables automated assessment of tumor cellularity, or tumor fraction, which is utilized to determine if there is sufficient tumor tissue to support advanced next generation sequencing (NGS) testing. Insufficient tumor DNA is a common failure mode in comprehensive genomic profiling and results in the destruction of precious tissue without molecular biomarker information to inform care decisions. AIM-TC solves for this by running on a standard hematoxylin and eosin (H&E) whole slide image and can automatically determine the tumor area and percentage of tumor nuclei.
As a molecular pathologist myself, I know how important accurate tumor cellularity assessment is. Many laboratories struggle with high NGS failure rates due to insufficient tumor content in the sample, leading to wasted time and expense. said Andy Beck M.D. Ph.D., Chief Executive Officer and Co-Founder of PathAI. Because of this, its become standard practice for pathologists to manually assess tumor fraction. We now have the opportunity to automate this step with AI, allowing pathologists to focus on other tasks.
Tumor cellularity assessment can be time consuming and onerous, particularly when the tumor content is low.2,3 For high volume laboratories, AIM-TC can reduce the amount of pathologist time spent on tumor cellularity assessments while also providing standardized, quantitative metrics to support more accurate determination of the required tissue inputs.
AIM-TC is a great example of how AI can augment the pathology laboratory and eliminate routine, stressful and time-consuming activities, allowing pathologists to focus on what they do best, said Tobias Kull, PhD., bioinformatician in the Molecular Pathology Unit of University Hospital Zurich. We expect that if implemented widely in our practice, AIM-TC can save hundreds of hours of pathologist time that can instead be used for case sign-off and patient care.
AIM-TC is currently available in Non-Small Cell Lung Cancer (NSCLC) and will be launched in 12 additional tumor types (including breast cancer, colorectal cancer, prostate cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, renal cell carcinoma, hepatocellular carcinoma, and urothelial carcinoma) in the coming months.
To learn more about AISight, PathAIs Image Management System, or AIM-TC, please visit our website, request a meeting with our team, or visit us at PathVisions in Orlando, Florida (Booth #206; October 29-31, 2023).
1 AIM Tumor Cellularity and AISight are Research Use Only. Not for use in diagnostic procedures.
2 Smits AJ, et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol. 2014 Feb;27(2):168-74.
3 Viray H, et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med. 2013 Nov;137(11):1545-9.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com.
Contact Details
SVM Public Relations and Marketing Communications
Maggie Naples
+1 401-490-9700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/pathai-announces-launch-of-aim-tumorcellularity-aim-tc-an-ai-based-tumor-cellularity-assessment-product-to-inform-advanced-molecular-testing-516158480
PathAI
COMTEX_442070493/2655/2023-10-18T09:59:27
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Smart Herald journalist was involved in the writing and production of this article.